Zogenix to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Zogenix (NASDAQ: ZGNX) announced management participation in two investor conferences: the Raymond James Human Health Innovation Conference on June 23, 2021, focusing on epilepsy treatment advancements, and the SVB Leerink CNS Forum on June 29, 2021, discussing underappreciated assets. Presenters include Michael Smith, CFO, and Stephen Farr, CEO. Zogenix is committed to therapies for rare diseases, with FDA-approved FINTEPLA for Dravet syndrome and ongoing development for other conditions like Lennox-Gastaut syndrome.

EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of its management team will participate in two upcoming investor conferences: the Raymond James Human Health Innovation Conference and SVB Leerink CNS Forum.

Raymond James Human Health Innovation Conference
Panel:	Recent Advancements & Future Directions in the Treatment of Epilepsy
Date:	Wednesday, June 23, 2021
Time:	4:00 PM Eastern Time
Presenter:	Michael Smith, Executive Vice President and Chief Financial Officer
SVB Leerink CNS Forum
Fireside Chat:	Reviewing Two Underappreciated Zogenix Assets
Date:	Tuesday, June 29, 2021
Time:	11:50 AM Eastern Time
Presenters:	Stephen J. Farr, Ph.D., President and Chief Executive Officer and Michael Smith, Executive Vice President and Chief Financial Officer

About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA^® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

CONTACTS:

Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com

Investors
Brian Ritchie 
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com

Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com

FAQ

What is the date and time of Zogenix's participation in the Raymond James Human Health Innovation Conference?

Zogenix will participate on June 23, 2021, at 4:00 PM Eastern Time.

Who will present at the SVB Leerink CNS Forum for Zogenix?

Stephen J. Farr, Ph.D., and Michael Smith will present at the SVB Leerink CNS Forum.

What is the focus of Zogenix's presentation at the Raymond James Conference?

The focus is on recent advancements and future directions in the treatment of epilepsy.

When will Zogenix discuss its underappreciated assets?

This discussion will take place on June 29, 2021, during the SVB Leerink CNS Forum.

What is Zogenix's primary product and its indication?

Zogenix's primary product is FINTEPLA, used for treating seizures associated with Dravet syndrome.